Monopar Therapeutics (NASDAQ:MNPR) Stock: Insider Kim Tsuchimoto Sells 1,199 Shares

Monopar Therapeutics Inc. (NASDAQ:MNPR) Director Kim Tsuchimoto sold 1,199 shares of the business’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $70.10, for a total value of $84,049.90. Following the completion of the transaction, the director owned 1,199 shares in the company, valued at $84,049.90. This trade represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Monopar Therapeutics Stock Up 4.2%

MNPR traded up $2.92 on Wednesday, hitting $72.81. 189,611 shares of the company traded hands, compared to its average volume of 143,006. The company has a 50 day moving average of $88.66 and a 200-day moving average of $77.40. The stock has a market capitalization of $488.56 million, a PE ratio of -33.55 and a beta of 1.62. Monopar Therapeutics Inc. has a 12-month low of $50.07 and a 12-month high of $124.82.

Monopar Therapeutics (NASDAQ:MNPR) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.02. On average, research analysts anticipate that Monopar Therapeutics Inc. will post -2.98 EPS for the current year.

Institutional Trading of Monopar Therapeutics

A number of institutional investors have recently bought and sold shares of MNPR. Siren L.L.C. grew its holdings in Monopar Therapeutics by 27.2% in the first quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock valued at $14,800,000 after purchasing an additional 57,820 shares during the last quarter. ADAR1 Capital Management LLC raised its stake in shares of Monopar Therapeutics by 13.0% during the 1st quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock worth $14,480,000 after buying an additional 30,370 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Monopar Therapeutics during the 2nd quarter worth $7,124,000. Walleye Capital LLC purchased a new stake in shares of Monopar Therapeutics in the 1st quarter worth about $3,458,000. Finally, Bank of America Corp DE boosted its position in shares of Monopar Therapeutics by 838.2% in the 1st quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock worth $3,271,000 after buying an additional 53,336 shares in the last quarter. 1.83% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. UBS Group set a $125.00 price target on Monopar Therapeutics in a report on Thursday, July 23rd. Zacks Research cut shares of Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 13th. BTIG Research upped their price objective on shares of Monopar Therapeutics from $117.00 to $133.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Thursday, October 15th. Finally, Wall Street Zen cut shares of Monopar Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, October 10th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Monopar Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $122.00.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing investigational therapies for cancer. The company’s research programs are centered on radiopharmaceuticals and oncology treatments intended to improve the diagnosis and treatment of serious malignancies.

Monopar’s pipeline includes MNPR-101-Zr, a zirconium-89-labeled antibody fragment being developed as a positron emission tomography imaging agent targeting the urokinase plasminogen activator receptor, or uPAR.